Kodak expands pharmaceuticals portfolio with four regulated products

Eastman Kodak (KODK) Company announced the expansion of its pharmaceuticals portfolio with four new regulated products: KODAK Phosphate Buffered Saline 1X in low endotoxin and RNase/DNase/Protease-free formulations, and KODAK Water for Injection in standard and RNase/DNase/Protease-free formulations. All are immediately available for order by U.S. research laboratories, biopharma developers, and contract development and manufacturing organizations, the company said in a statement. Kodak says the new cGMP-compliant pharmaceuticals production facility in Rochester, N.Y. advances the organization’s sustainability commitment through energy-efficient lighting and custom process equipment to reduce greenhouse gas emissions, plus a water sterilization system that minimizes consumption and waste.